Company Directory

Global viral vector CDMO for cell and gene therapy

Oxford Biomedica (OXB) is a global contract development and manufacturing organisation specialising in viral vectors for cell and gene therapy. The company provides lentiviral, adeno-associated virus (AAV), and adenoviral vector development and manufacturing services from early-stage process development through to commercial-scale GMP manufacture. OXB is headquartered in Oxford and operates manufacturing sites across Oxfordshire, France, and the United States.

Automated bioreactor platform for cell and gene therapy manufacturing

microfluidX is a UK instruments company developing automated bioprocessing platforms for cell and gene therapy research and manufacturing. Its core product is a microfluidics-based bioreactor system designed for parallel cell culture process development and scalable cell expansion. The platform integrates online process analytical tools and data analytics and is intended to support the development and manufacture of autologous cell and gene therapies from research scale through to clinical and commercial production.

Generative AI platform for TCR therapy design and immune repertoire analysis

Synteny Biotechnology is a biotechnology company developing a platform that combines high-throughput TCR-antigen data generation with generative AI to design precision T cell receptor therapies for cancer. The platform addresses a critical bottleneck in the field, namely the scarcity of paired TCR-epitope interaction data, using protein language models to engineer TCRs with improved tumour specificity and reduced cross-reactivity. The company applies this platform to an internal pipeline of TCR bispecific therapeutic candidates.

Transformative medicines for cystic fibrosis and serious genetic diseases

Vertex Pharmaceuticals is a global biopharmaceutical company with its European R&D headquarters at Milton Park, Oxfordshire, and its international commercial headquarters in London. The Oxford site conducts full-spectrum drug discovery encompassing human genetics, structural biology, and medicinal chemistry, and has been central to Vertex's development of approved therapies for cystic fibrosis. The company's broader pipeline addresses sickle cell disease, beta-thalassaemia, pain, and kidney disease, including gene-edited cell therapies.

Synthetic promoter platform for precision gene expression control

Chromatin Bioscience designs synthetic promoters and gene expression control systems for cell and gene therapy developers. Its platform uses bioinformatics to identify cell-type-selective regulatory elements from the human genome, which are assembled into novel synthetic promoters enabling precise, durable and targeted transgene expression. The company's promoters are integrated into partner programmes across oncology, nephrology and rare disease gene therapies, with a clinical-stage collaboration supporting an in vivo CAR-T candidate for multiple myeloma.

Next-generation lateral CAR-T therapies for refractory solid tumours

Leucid Bio Ltd is a clinical-stage biotechnology company developing next-generation CAR-T cell therapies for hard-to-treat solid tumours. Founded on over two decades of King's College London research, the platform redesigns the CAR signalling architecture to enhance T-cell potency, persistence, and tumour infiltration. Lead asset LEU011 targets NKG2D stress ligands expressed on over 80% of human tumours and is being evaluated in the Phase I/IIa AERIAL multi-centre dose-escalation trial, manufactured at Great Ormond Street Hospital's GMP facilities.

Next-generation programmable gene insertion platform technology

Gene Weaver is a preclinical-stage biotechnology company developing a programmable RNA-based gene insertion system. Its enzymatic system enables targeted insertion of large DNA payloads at virtually any genomic site without introducing double-strand breaks, addressing key limitations of existing tools including variable site integration and restricted payload size. The company received a $515,000 grant from the Bill and Melinda Gates Foundation in May 2025 to advance the technology toward gene therapy and affordable protein therapeutic manufacturing applications.

UK commercial base for a rare metabolic disease biotech

Amicus Therapeutics UK is the British subsidiary of Amicus Therapeutics, a US-listed biotechnology company focused on rare metabolic diseases. The company develops enzyme replacement therapies and gene therapies targeting lysosomal storage disorders, with approved medicines for Pompe disease and Fabry disease. The UK office in Marlow serves as the commercial and medical affairs base for Great Britain and Ireland.

Engineered immune cells as living delivery vehicles for genetic medicines

Dart Biosciences is a biotechnology company developing a platform that uses engineered immune cells as living delivery vehicles for genetic medicines. By leveraging immune cells' natural ability to localise to disease-relevant tissues, the platform aims to achieve more spatially precise genetic payload transfer with reduced systemic exposure compared to viral vectors and lipid nanoparticles. The modular architecture is designed to support conditional payload release and repeat administration across multiple disease areas.

Gene therapy company targeting complement-mediated ocular diseases

Complement Therapeutics is a clinical-stage biotechnology company developing gene therapies and protein-based therapeutics for diseases driven by dysregulation of the complement immune pathway. A spin-out from the University of Manchester, the company's lead programme CTx001 is an AAV-based gene therapy for geographic atrophy, an advanced form of dry age-related macular degeneration. The company is also developing the Complement Precision Medicine platform for quantification of complement cascade proteins to support diagnosis and patient stratification.

Robotic automation platform for scalable cell therapy manufacturing

Cellular Origins is a biotechnology company developing robotic automation systems for the industrial-scale manufacture of cell therapies. Its platform uses mobile robotics and automated sterile fluidic interconnection to link existing bioprocess instruments into fully automated, GMP-compliant manufacturing workflows. The platform is designed to scale production without requiring therapy redevelopment or process change. Cellular Origins partners with cell therapy developers and equipment manufacturers including Cytiva, Fresenius Kabi and Thermo Fisher Scientific.

AI-driven intron technology to enhance transgene expression

ExpressionEdits is a biotechnology company developing computational tools to improve protein expression from artificial gene constructs. Its Genetic Syntax Engine uses machine learning and biological data to predict optimal intron insertion patterns within transgenes, increasing protein production levels in mammalian systems. The platform has applications across gene therapy, biologics development and recombinant protein manufacturing. The company is a spin-out from the University of Cambridge and has a collaboration with Boehringer Ingelheim.